Ocugen’s Gene Therapy Candidates Race Toward FDA Filings, But the Market Isn’t Ready to Celebrate

Ocugen is making quiet but meaningful progress across its pipeline of gene therapy programmes, yet the stock tells a more cautious story. Shares ended the week at €1.18, sliding 5.29% on Friday alone and extending a monthly rout of 26.22%. The collapse has pushed the relative strength index to 25.3 — territory typically signalling deep oversold conditions. Both the 50-day moving average of €1.57 and the 200-day line of €1.29 now sit well above the current price, underscoring the market’s reluctance to reward operational advances with capital appreciation.

The disconnect stems partly from the company’s latest quarterly report. Revenues came in at $1.53 million, handily beating consensus, but a per-share loss of $0.06 disappointed investors. Operating costs climbed roughly a fifth year-on-year, weighing on the bottom line. The market appears to be looking past the top-line beat and focusing instead on the widening deficit.

Ocugen has, however, strengthened its financial position in a meaningful way. A recently closed private placement of $115 million in convertible notes, carrying a 6.75% coupon, extends the company’s cash runway through 2028. Management expects pro-forma liquidity of around $112 million after the transaction closes. A significant portion of the proceeds — roughly $32.7 million — has already been used to retire more expensive debt. The former credit facility carried a punishing 12.5% interest rate, so the refinancing should cut Ocugen’s annual interest burden substantially.

The extra breathing room is critical because the pipeline is entering a period dense with catalysts. The lead asset, OCU400, a gene therapy for retinitis pigmentosa, has completed enrolment of 140 patients in its pivotal Phase 3 liMeliGhT study. Ocugen plans to initiate a rolling biologics licence application (BLA) in the third quarter of 2026, with completion targeted for mid-2027. Preparations for commercial-scale production are already under way.

Should investors sell immediately? Or is it worth buying Ocugen?

Another late-stage candidate, OCU410ST, targets Stargardt disease, a rare inherited retinal condition affecting roughly 100,000 people in the US and Europe for which no FDA-approved treatment currently exists. The confirmatory GARDian3 study enrolled 63 patients ahead of schedule. Top-line data are expected in the first half of 2027, and if positive, a BLA submission would follow. The gap to those results remains wide, which helps explain why the stock hasn’t rallied on the news alone.

Ocugen is also advancing OCU410, a therapy for geographic atrophy secondary to dry age-related macular degeneration. A registrational Phase 3 study is slated to begin in the third quarter of 2026. First interim results from an earlier-stage programme, OCU410ST, are also anticipated around that time.

Management plans to use an upcoming Stifel Virtual Ophthalmology Forum at the end of May to pitch the timeline to a broader investor audience. The immediate focus, however, will be on concrete execution. The start of the rolling BLA for OCU400 in Q3 2026 marks the next critical milestone. Should Ocugen hit that target, the market may finally begin to close the gap between the stock’s depressed valuation and the operational strides the company is making.